| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000044428 |
| Receipt No. | R000050525 |
| Scientific Title | Clinical Trial Mock Simulation Research Plan Phase IIb Trial in Fistulising Crohn's Disease |
| Date of disclosure of the study information | 2021/06/04 |
| Last modified on | 2022/03/01 (Ver. 6) |
| Basic information | ||||
| Public title | Clinical Trial Mock Simulation Research Plan
Phase IIb Trial in Fistulising Crohn's Disease |
|||
| Acronym | Clinical Trial Mock Simulation Research Plan
Phase IIb Trial in Fistulising Crohn's Disease |
|||
| Scientific Title | Clinical Trial Mock Simulation Research Plan
Phase IIb Trial in Fistulising Crohn's Disease |
|||
| Scientific Title:Acronym | Clinical Trial Mock Simulation Research Plan
Phase IIb Trial in Fistulising Crohn's Disease |
|||
| Region |
|
|||
| Condition | ||
| Condition | Fistulising Crohn's Disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The objective of this clinical trial mock simulation is to gather patient and healthcare provider
(HCP) feedback about the design of a Phase IIb trial in fistulising CD in order to: Understand patient and caregiver needs and expectations Deliver on patient and caregiver needs in BI trial and non-trial activities Raise patient satisfaction with BI trials, medicines and support services Enhance disease awareness and patient information Support patient access to care and healthcare services Understand and support the objectives of patient organisations |
| Basic objectives2 | Others |
| Basic objectives -Others | Not applicable |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Experience with conducting clinical trials, e.g. investigator or study coordinator |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | PATIENTS
Diagnosis of fistulising CD Male or female patients 18+ years old HEALTH CAREPROFESSIONAL Experience with conducting clinical trials, e.g. investigator or study coordinator From the same country as the patient with whom they will participate in the virtual trial visit simulation |
|||
| Key exclusion criteria | None | |||
| Target sample size | 12 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Nippon Boehringer Ingelheim Co., Ltd. | ||||||
| Division name | Medicine Division | ||||||
| Zip code | 141-6017 | ||||||
| Address | 2-1-1 Osaki, Shinagawa-ku, Tokyo, Japan | ||||||
| TEL | 03-6417-2043 | ||||||
| nobutaka.yagi@boehringer-ingelheim.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Nippon Boehringer Ingelheim Co., Ltd. | ||||||
| Division name | Medicine Division | ||||||
| Zip code | 141-6017 | ||||||
| Address | 2-1-1 Osaki, Shinagawa-ku, Tokyo, Japan | ||||||
| TEL | 03-6417-2043 | ||||||
| Homepage URL | |||||||
| nobutaka.yagi@boehringer-ingelheim.com | |||||||
| Sponsor | |
| Institute | Nippon Boehringer Ingelheim Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nippon Boehringer Ingelheim Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Medical Corporation Kyoso-kai AMC Nishi-Umeda Clinic Ethics Review Committee |
| Address | Maruit Nishi-Umeda Building 3F, 3-3-45 Umeda, Kita-ku, Osaka-shi, Osaka, Japan |
| Tel | 06-4797-5660 |
| morikawa@amc-clinic.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 3 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Non-interventional study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050525 |